Array BioPharma (ARRY) PT Lifted to $15 at Piper Jaffray; Proforma Cash Of $222 Million To File NDAs
Tweet Send to a Friend
Piper Jaffray analyst Edward Tenthoff boosted his price target on Overweight-rated Array BioPharma (NASDAQ: ARRY) to $15.00 (from $9.00) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
